NEW YORK, Jan. 4, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agile Therapeutics, Inc. ("Agile" or the "Company") (NASDAQ: AGRX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Agile and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 3, 2017, post-market, Agile Therapeutics released data from its Phase 3 SECURE study assessing its combined hormonal contraceptive patch Twirla, conducted at the request of the U.S. Food and Drug Administration following its rejection of Agile Therapeutic's initial marketing application in 2013. In a press release, the Company referred to "positive top-line results" in the study, yet reported that 1.7% of subjects experienced "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." In addition, 51.4% of subjects discontinued the study.
On this news, Agile Therapeutics stock has fallen as much as $3.18, or 63.6%, to $1.82 during intraday trading on January 4, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agile-therapeutics-inc---agrx-300385674.html